Angiogenic Biomarkers in Preeclampsia

Abstract

(Obstet Gynecol. 2024;143(4):515–523. doi:10.1097/AOG.0000000000005532) Preeclampsia, a dangerous condition affecting 3% to 4% of pregnancies in the United States, causes significant maternal and neonatal complications worldwide. Monitoring for severe features is crucial for timely intervention. While it often develops from nonsevere hypertensive disorders, recent advancements include the use of 2 angiogenic biomarkers, soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF), to predict its onset and severity. These biomarkers have been integrated into diagnostic assays in various regions, including Europe and parts of Asia and the Americas. The Food and Drug Administration (FDA) recently authorized the sFlt-1/PlGF test (KRYPTOR Test System) for use in the United States to aid in assessing the risk of progression to severe preeclampsia in hospitalized pregnant women. However, it is emphasized that these tests should complement, not replace, clinical judgment.